Status:
TERMINATED
Acute Labetalol Use in Preeclampsia
Lead Sponsor:
Albany Medical College
Conditions:
Preeclampsia With Severe Features
Eligibility:
FEMALE
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to understand if administration of a personalized dose of the anti-hypertensive medication, labetalol, based on patient's body-mass index, will be more effective at contro...
Detailed Description
The investigators seek to asses the effect of obesity (BMI\>30) on severe hypertension control in patients with preeclampsia with severe features. The investigators hypothesize that successive adminis...
Eligibility Criteria
Inclusion
- BMI ≥ 30
- Age ≥ 18 years
- Gestational age ≥ 24 weeks
- Singleton gestation
- One sustained severe range blood pressure at Albany Medical Center
Exclusion
- Known allergic reaction to labetlol
- Persistent mild-moderate asthma (≥ 2 rescue inhaler uses per week in the previous month)
- Obstructive airway disease
- Bradycardia \< 70 beats/min
- Heart block \> 1st degree or history of heart failure
Key Trial Info
Start Date :
February 18 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 20 2020
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT03872336
Start Date
February 18 2019
End Date
July 20 2020
Last Update
July 22 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Albany Medical Center Obstetrics and Gynecology
Albany, New York, United States, 12208